Selvita is a $225m Polish oncology focused biotechnology company. Broad oncology targeted therapeutics pipeline includes kinase inhibitor and synthetic lethality programs. Lead programs include SEL24, a first in class PIM/FLT3 kinase inhibitor in Ph 1/2 in AML (partnered with Menarini) and SEL120, a small molecule selective CDK8 inhibitor currently in IND enabling studies for leukemias, lymphomas, and solid tumors, with Ph 1/2 initiation expected early 2019. Earlier stage pipeline from Cancer Cell Metabolism and Immunometabolism Platform and Immunooncology Platform. Drug discovery services business with 50+ biopharma partners (1H18 revenue of PLN 27.9 M/$7M).
Park Life Science
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.